Skip to main content
Signal8

CDT Equity Inc. (CDT)

CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

CDT Equity Inc. logo

CDT Equity Inc.

NASDAQ:CDTHealthcare
AH+5.56%$0.3800
Close$0.3600-4.51%
Mkt Cap$684K
EV-
Float1.76M
O/S1.9M
VOL317K sh
$ Vol$115K
RVOL0.13×
Inst Own0.0%
SI0.3%
Net Cash/Sh-
Dilution
CDT Equity Inc. logoNASDAQ:CDTAH$0.3800+5.56%
Financials Summary
Revenue$0
Net Income-$39.22M
Total Assets$3.54B
Free Cash Flow-$17.96M
Debt & Equity
Debt 50%
Equity 50%
Total Debt$1.29B
Total Equity$1.26B
Shares Outstanding
Short Interest

No short interest data available.

Split History8 splits · 8 reverse
2-year cumulative
1:1,500,000,000Over cap

Past the 1:250 Nasdaq cap, ineligible for a bid-price compliance period

  1. 1:20Reverse split
    Nov 6, 202620 shares → 1
  2. 1:25Reverse split
    Sep 29, 202625 shares → 1
  3. 1:10Reverse split
    Jul 20, 202610 shares → 1
  4. 1:25Reverse split
    Mar 27, 202625 shares → 1
  5. 1:8Reverse split
    Oct 13, 20258 shares → 1
  6. 1:15Reverse split
    May 20, 202515 shares → 1
  7. 1:100Reverse split
    Jan 27, 2025100 shares → 1
  8. 1:2Reverse split
    Jul 15, 20042 shares → 1
Balance Sheet Details
Assets$3.54B
Liabilities$2.28B
Accounts Receivable$462.85M
Accounts Payable$361.43M
Inventory$402.35M
PP&E (Net)$566.02M
Goodwill$1.04B
Intangible Assets$399.8M
Income Statement
PeriodFY 2025FY 2024FY 2023FY 2022FY 2021
CurrencyUSDUSDUSDUSDUSD
Period Ending2025-12-312024-12-312023-12-312022-12-312021-12-31
Revenue$0$0$0$0$0
YoY Growth-----
Cost of Revenue$0$0$0$0$0
Gross Profit$0$0$0$0$0
Gross Margin-----
Research and Development$5.05M$3.38M$90K$111K$283K
Selling, General, and Administrative$31.7M$12.04M$5.17M$3.05M$2.89M
Other$0$0$0$0$0
Total Operating Expenses$36.76M$15.42M$5.26M$3.16M$3.17M
Operating Income (EBIT)-$36.76M-$15.42M-$5.26M-$3.16M-$3.17M
Operating Margin-----
Interest Expense$319K$1.51M$211K$0$0
Interest Income$28K$13K$15K$1.98M$0
Other Income (Expense)-$2.47M-$2.38M$8.1M-$1.73M-$484K
Income Before Tax (EBT)-$39.22M-$17.8M$2.84M-$4.89M-$3.66M
Income Tax Expense$0$0$0$0$0
Net Income-$39.22M-$17.8M-$535K-$4.89M-$3.66M
Net Income Margin-----
Supplementary Data
EPS-11778.00-615930.00-23970.00-201360.00-750.00
Diluted EPS-11778.00-615930.00-267600.00-201360.00-750.00
Weighted Average OS3,3302922245.762
EBITDA-$36.48M-$15.84M$3.05M-$4.89M-$3.66M
EBITDA Margin-----
Balance Sheet
PeriodFY 2025FY 2024FY 2023FY 2022FY 2021
CurrencyUSDUSDUSDUSDUSD
Period Ending2025-12-312024-12-312023-12-312022-12-312021-12-31
Assets
Current Assets
Cash and Cash Equivalents$389.89M$554K$4.23M$0$49K
Short-Term Investments$0$0$0$0$0
Cash and Short-Term Investments$389.89M$554K$4.23M$0$49K
Accounts Receivable$462.85M$489K$0$0$0
Inventory$402.35M$0$0$0$0
Other Current Assets$94.3M$0$0$0$0
Total Current Assets$1.35B$2.71M$5.73M$0$104K
Long-Term Assets
Property, Plant & Equipment Net$566.02M$303K$0$0$0
Goodwill$1.04B$1.02B$0$0$0
Intangible Assets$399.8M$419.07M$0$5K$0
Long-Term Investments$0$0$0$0$0
Deferred Tax Assets$14.51M$0$0$0$0
Other Long-Term Assets$177.09M-$1.44M$1.49M$0$109K
Total Long-Term Assets$2.19B$1.48M$1.49M$5K$109K
Other Assets$0$0$0$0$0
Total Assets$3.54B$4.19M$7.22M$5K$213K
Liabilities
Current Liabilities
Accounts Payable$361.43M$1.43M$215K$0$0
Short-Term Debt$0$7.23M$985K$175K$177K
Current Income Tax Payable$0$0$0$375K$0
Current Unearned Revenue$0$0$0$0$0
Other Current Liabilities$0$0$0$3K$15K
Total Current Liabilities$697.5M$10.74M$1.8M$4K$193K
Long-Term Liabilities
Long-Term Debt$1.29B$0$0$1.83M$0
Long-Term Unearned Revenue$0$0$0$4.63M$0
Long-Term Deferred Tax Liabilities$98.06M$0$0$0$0
Other Long-Term Liabilities$197.97M$138K$5.88M-$546$0
Total Long-Term Liabilities$1.58B$245K$5.88M$6K$0
Other Liabilities$0$0$0$0$0
Total Liabilities$2.28B$10.99M$7.68M$10.09M$193K
Stockholders' Equity
Preferred Stock$0$0$0$0$0
Common Stock$503K$14K$7K$6K$331
Retained Earnings$1.41B-$29.1M-$11.3M-$10.77M-$4K
Comprehensive Income & Other-$97.2M$414K$411K$675K$0
Other Stockholders' Equity-$141.65M$22.29M$10.84M$675K$25K
Total Equity$1.26B-$6.79M-$457K-$10.09M$21K
Minority Interest$0$0$0$0$0
Total Liabilities and Equity$3.54B$4.19M$7.22M$5K$213K
Supplementary Data
Total Debt$1.29B$7.46M$985K$2.01M$177K
Net Debt$895.78M$6.9M-$3.24M$2K$129K
Cash Flow Statement
PeriodFY 2025FY 2024FY 2023FY 2022FY 2021
CurrencyUSDUSDUSDUSDUSD
Period Ending2025-12-312024-12-312023-12-312022-12-312021-12-31
Operating Activities
Net Income-$39.22M-$17.8M-$535K-$4.89M-$3.66M
Depreciation & Amortization$2.42M$457K$0$0$0
Deferred Income Tax$0$0$0$0$0
Stock-Based Compensation$2.18M$1.63M$199K$0$0
Changes in Working Capital:
  Accounts Receivable$0$0$0$0$0
  Inventory$0$0$0$0$0
  Accounts Payable$434K$1.23M$215K$0$0
  Other Working Capital$4.29M-$1.37M-$2.73M$596K$1.36M
Total Working Capital Change$4.73M-$142K-$2.52M$596K$1.36M
Other Non-Cash Items$14.33M$6.17M-$4.87M$2.02M$149K
Net Cash from Operating-$15.55M-$9.68M-$7.72M-$2.27M-$2.15M
Investing Activities
Capital Expenditures-$405K-$51K$0$0$0
Acquisitions$0$0$0$0$0
Purchases of Investments$0-$490K$0$0$0
Sales of Investments$0$498K$497K$148K$0
Other Investing Activities-$403K$0$228K-$331K$0
Net Cash from Investing-$808K-$43K$725K-$183K$0
Financing Activities
Debt Repaid----$1.11M-$688K
Common Stock Issuance$19.7M$3.33M$150K$1.34M$1.21M
Common Stock Repurchases-$106K$0$0$0$0
Dividends Paid$0$0$0$0$0
Other Financing Activities$0$289K$8.49M$0$0
Net Cash from Financing$17.42M$6.07M$10.93M$2.45M$1.9M
Forex Effect-$104K-$16K$299K$1K$1K
Net Change in Cash$955K-$3.67M$4.23M$0-$252K
Supplementary Data
Operating Cash Flow-$15.55M-$9.68M-$7.72M-$2.27M-$2.15M
Capital Expenditure-$2.4M-$51K$0$0$0
Free Cash Flow-$17.96M-$9.73M-$7.72M-$2.27M-$2.15M
Cash at Beginning$554K$4.23M$0$0$252K
Cash at End$1.51M$554K$4.23M$0$0